{"product_id":"vnrx-ansoff-analysis","title":"(VNRX) VolitionRx Limited ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplore the Complete Growth Strategy Behind the Preview\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis VolitionRx Limited Ansoff Matrix Analysis helps you quickly assess the company’s growth choices—market penetration, market development, product development, and diversification—in a concise, actionable format; the page already includes a real preview\/sample of the analysis so you can judge style and substance before buying. Purchase the full version to receive the complete, ready-to-use company-specific report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNu.Q cancer test share gain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNu.Q is VolitionRx Limited's core human cancer blood test, so market penetration means getting more use of the same assay in the cancer-testing markets it already serves. That matters in a market with about 20 million new cancer cases in 2022, giving the test a very large installed-use pool without needing a new product launch.\u003c\/p\u003e\n\u003cp\u003eThe share gain path is simple: win more labs, more clinicians, and more repeat orders for the same test. If Nu.Q can take a small share of even one screening or monitoring segment, the revenue lift can be meaningful because adoption scales inside the existing market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNu.Q Vet veterinary channel depth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNu.Q Vet is already built for animal health, so market penetration here means getting more vets and pet-health providers to use the same test more often, without changing the product or market. That is the lowest-risk Ansoff move because it stays on existing ground and aims to raise usage, repeat orders, and clinic adoption. In 2025, VolitionRx still had no separate Nu.Q Vet revenue split disclosed, so the main metric is channel depth, not new-market entry.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNu.Q Nets immune monitoring adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNu.Q Nets is a ready-made immune-monitoring product, so market penetration means pushing deeper into existing immune-health workflows rather than changing the core test. The play is to grow adoption in clinics, labs, and research settings by fitting into current monitoring routines, where one additional test can lift volume without new product risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNucleosomics platform customer stickiness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVolitionRx Limited's Nucleosomics platform can lift stickiness by tying one blood draw to multiple tests, so each new assay makes the workflow harder to replace. In FY2025, the key signal is not scale but retention: recurring test use and broader menu adoption should raise switching costs and deepen account penetration. If one lab workflow already supports several Volition tests, displacement gets materially harder.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne platform, multiple tests.\u003c\/li\u003e\n\u003cli\u003eMore tests, higher switching costs.\u003c\/li\u003e\n\u003cli\u003eWorkflow fit drives retention.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCapture and Discover cross-sell\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNu.Q Capture and Nu.Q Discover lift VolitionRx Limited's market penetration by selling add-on tools into the same lab workflows, so each existing customer can generate more assay use. Capture concentrates samples to improve diagnostic precision, while Discover profiles nucleosomes, which deepens attachment in current accounts. That is a direct cross-sell lever.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame workflow, higher attach rate\u003c\/li\u003e\n\u003cli\u003eMore value per existing customer\u003c\/li\u003e\n\u003cli\u003eStronger diagnostic precision\u003c\/li\u003e\n\u003cli\u003eDeeper use of Nu.Q tests\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVolitionRx’s Big Growth Lever: More Nu.Q Use, Same Customer Base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMarket penetration for VolitionRx Limited is about driving more use of Nu.Q, Nu.Q Vet, and Nu.Q Nets inside the same customer pools. With about 20 million new cancer cases in 2022, the human test has a large base, while 2025 still showed no separate Nu.Q Vet revenue split.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\/2022\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew cancer cases\u003c\/td\u003e\n\u003ctd\u003e20 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNu.Q Vet revenue split\u003c\/td\u003e\n\u003ctd\u003eNot disclosed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eMaps out VolitionRx Limited’s growth options across existing and new products and markets using the Ansoff Matrix\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick, structured Ansoff view to simplify VolitionRx Limited’s growth planning and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eConsolidates credible primary and secondary sources to validate Ansoff Matrix growth assumptions for VolitionRx, expediting due diligence and traceable strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNu.Q new geography rollout\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVolitionRx can use market development by rolling Nu.Q into new regions such as Europe, Asia-Pacific, and the Middle East while keeping the test unchanged. This fits its international detection focus: the same blood-based platform, more hospitals, labs, and payers. The upside is reach, not redesign.\u003c\/p\u003e\n\u003cp\u003eThat matters because the company is still in commercialization mode, so each new geography can add test volumes faster than new product R\u0026amp;D. In Ansoff terms, this is the lowest-change growth path: same Nu.Q, larger addressable market. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNu.Q Vet cross-border animal health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNu.Q Vet uses existing cancer-screening tech and can be sold into new veterinary geographies and animal-health channels beyond VolitionRx Limited's current base. In 2025, this market-development play targets two levers: broader country rollout and more clinic\/lab distribution, without changing the core product. That lowers R\u0026amp;D spend but raises commercial execution risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNu.Q Nets broader clinical segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNu.Q Nets can expand from immune health monitoring into adjacent patient-monitoring and clinical-decision segments without changing the product. That is classic market development: same assay, broader customer set, especially hospitals, labs, and care teams that need faster immune-status insight. VolitionRx Limited can grow usage by selling into new clinical workflows where decision speed matters.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNucleosomics research market expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNucleosomics is VolitionRx Limited's core blood-test platform, and moving it into broader research and translational-diagnostics use is a clear new-market play. Nucleosome profiling has wide scientific value because it can track disease biology from blood, which supports adoption beyond one test or one care setting.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame platform, new buyers\u003c\/li\u003e\n\u003cli\u003eBroader use in research and diagnostics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOther disease detection use cases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVolitionRx Limited’s blood-test platform is built for cancer and other diseases, so the same sample workflow can be extended into new screening and monitoring uses without changing the core product family. That creates market-development upside in adjacent disease areas where a simple blood draw can fit existing clinical routines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame assay architecture\u003c\/li\u003e\n\u003cli\u003eWider indication set\u003c\/li\u003e\n\u003cli\u003eMore screening channels\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe opportunity is strongest where physicians already order blood-based monitoring, because VolitionRx can add new disease targets faster than building a new test from scratch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVolitionRx’s Growth Play: Same Test, Bigger Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVolitionRx Limited’s market development is about selling the same Nu.Q platform into more geographies and channels, not changing the assay. In 2025, the best fit is Europe, Asia-Pacific, the Middle East, veterinary networks, and adjacent hospital workflows, so growth should come from more test volume, not higher R\u0026amp;D.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLever\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore asset\u003c\/td\u003e\n\u003ctd\u003eNu.Q, same test\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 focus\u003c\/td\u003e\n\u003ctd\u003eNew regions, new buyers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRisk\u003c\/td\u003e\n\u003ctd\u003eCommercial execution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eVolitionRx Limited Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNu.Q Capture enhancement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNu.Q Capture is a product development move because VolitionRx Limited is upgrading its diagnostic kit for the same core customers, not chasing a new market. It improves sample concentration, which can sharpen test precision and add usable functionality to the Nu.Q platform. In FY2025, this fits a company still focused on building assay value rather than broadening its customer base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNu.Q Discover profiling tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNu.Q Discover is VolitionRx Limited’s nucleosome profiling platform, so new product development can add richer biomarker panels and workflow features for existing diagnostics and research users. The company’s 2025 filings still show a cash burn business, with revenue far below operating spend, so upgrades that lift platform use matter.\u003c\/p\u003e\n\u003cp\u003eThis fits the Nucleosomics base by deepening use in blood-based research and diagnostics rather than opening a new market. If Nu.Q Discover improves sensitivity and sample insight, it can support higher-value repeat use in labs already working with nucleosome data.\u003c\/p\u003e\n\u003cp\u003eThe main upside is stronger customer lock-in and better fit with the clinical research market, where adoption depends on clear performance gains. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNu.Q Vet expanded test menu\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNu.Q Vet already covers animal cancer screening, so expanding the test menu is a clear product-development move for VolitionRx Limited. In 2025, the same companion-animal market can be served with deeper panels, which helps raise wallet share without changing the customer base. A broader veterinary toolkit can lift repeat use and support steadier revenue per clinic.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNu.Q Nets workflow upgrades\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNu.Q Nets workflow upgrades fit product development because VolitionRx Limited keeps the same immune monitoring market but improves the product for existing users. Better usability, reporting, and deeper analytics can raise adoption and retention without changing the target market. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame users, better product\u003c\/li\u003e\n\u003cli\u003eFocus on workflow speed\u003c\/li\u003e\n\u003cli\u003eImprove reports and analytics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHuman blood-test refinement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHuman blood-test refinement fits VolitionRx Limited’s product development move because Nu.Q is its flagship human blood-test brand for cancer detection, and upgrades to assay performance, sample handling, or reporting stay inside the same clinical market. This matches the company’s epigenetics and nucleosome platform, where small test gains can improve sensitivity, specificity, and lab workflow without changing the core use case.\u003c\/p\u003e\n\u003cp\u003eIn 2025, this kind of refinement matters more than broad new-market bets because it can deepen clinical adoption of Nu.Q while using the same biomarker science and regulatory path.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame clinical market\u003c\/li\u003e\n\u003cli\u003eBetter assay performance\u003c\/li\u003e\n\u003cli\u003eImproved sample handling\u003c\/li\u003e\n\u003cli\u003eClearer test reporting\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVolitionRx Should Double Down on Product Upgrades, Not Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProduct development is the right Ansoff move for VolitionRx Limited because Nu.Q Capture, Nu.Q Discover, Nu.Q Vet, Nu.Q Nets, and Nu.Q assay upgrades all deepen use in the same markets. In FY2025, revenue was still below operating spend, so higher-value features and better workflow matter more than market expansion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eBelow opex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFocus\u003c\/td\u003e\n\u003ctd\u003eSame users, better products\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAnimal health beyond screening\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNu.Q Vet gives VolitionRx Limited a real animal-health foothold, with 1 proven product line in veterinary cancer screening. Diversification would build on that base by adding new animal-health products for a new market, moving the Company beyond screening into broader diagnostics or monitoring. That shift can raise addressable demand, but it also adds execution risk because the new offer must win adoption outside oncology.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch-use nucleosome services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNu.Q Discover gives VolitionRx Limited a nucleosome profiling platform that can be sold as research-use tools, not just diagnostics. That is classic diversification: a new product for a new customer base, moving into the RUO market in 2025. If packaged as separate assays or analytics, it could broaden use beyond clinical labs into academic and pharma research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmune health monitoring solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNu.Q Nets is aimed at immune-system health, so a standalone immune-monitoring product for hospitals, wellness firms, or employers would be pure Diversification: a new offer in a new market. That would push VolitionRx Limited beyond its cancer-detection core and could widen revenue sources. As of FY2025, the company still relied mainly on Nu.Q cancer assets, so this move would be a major strategic reset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSample-concentration tools for other labs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNu.Q Capture could be turned into a stand-alone lab prep tool, so VolitionRx Limited would sell more than one product line and reduce its reliance on cancer-test workflows. That matters because sample-concentration tools improve assay precision, and a broader lab use case opens a new market outside core diagnostics.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew product: lab sample concentration\u003c\/li\u003e\n\u003cli\u003eUses beyond cancer testing\u003c\/li\u003e\n\u003cli\u003eLower dependence on one workflow\u003c\/li\u003e\n\u003cli\u003eBetter precision can support adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis is diversification in Ansoff terms: the same technology, but a wider customer base and a separate revenue stream. If other labs adopt Nu.Q Capture, VolitionRx Limited can spread product risk across research, clinical, and routine lab use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePlatform-based epigenetics applications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVolitionRx Limited’s Nucleosomics is a platform, not a single assay, so it can spawn new epigenetics products for new buyers beyond current blood-test customers. That makes it the broadest Ansoff diversification route: new products plus new end users, with a path into research, veterinary, and broader diagnostics markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePlatform-driven, not assay-only\u003c\/li\u003e\n\u003cli\u003eNew products can reach new buyers\u003c\/li\u003e\n\u003cli\u003eBroadest growth route in Ansoff\u003c\/li\u003e\n\u003cli\u003ePotential beyond blood-test users\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVolitionRx’s Nucleosomics Push Broadens Growth, But Adoption Risk Remains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVolitionRx Limited’s diversification path is broadest in Nucleosomics: a platform, not a single assay, can support new products for new buyers across research, veterinary, and broader diagnostics. In FY2025, the Company still leaned mainly on Nu.Q cancer assets, so diversification would reduce single-line risk but raise adoption risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eFY2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNu.Q Vet\u003c\/td\u003e\n\u003ctd\u003e1 proven veterinary line\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNu.Q Discover\u003c\/td\u003e\n\u003ctd\u003eRUO market in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNu.Q Nets\u003c\/td\u003e\n\u003ctd\u003eNew immune-monitoring market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNu.Q Capture\u003c\/td\u003e\n\u003ctd\u003eNew lab tool use case\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235158565129,"sku":"vnrx-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/vnrx-ansoff-matrix.webp?v=1785735496","url":"https:\/\/dcfanalyst.com\/products\/vnrx-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}